Debates and Dilemmas, Part 1: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in Whom

Access Course

 

Debates and Dilemmas, Part 1: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in WhomExperts discuss two cases on first-line management of advanced non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs).

 

This activity is intended for hematologists/oncologists, pulmonologists, pathologists, and nurses. 

 

 

 

 

 

 

Approximate Time to Complete: 30 minutes

 

Credit Available: Nov. 26, 2018- Nov. 26, 2019

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding clinical trial data on the use of ICIs alone or in combination in first-line management of advanced NSCLC
  • Have greater competence related to identifying patients with advanced NSCLC who may benefit from the use of ICIs
  • Have greater competence related to management of irAEs in patients with advanced NSCLC
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.50
(0.5 contact hours in the area of pharmacology)
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50
(0.5 contact hours are in the area of pharmacology)
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.50